España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Entrada Therapeutics
TRDA
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$13.06
0.37
2.92%
At close: -
$13.06
0.00
0.00%
After Hours: 4:00 PM EDT
Get Report
Comment
Entrada Therapeutics (TRDA) Forecast
News
Earnings
Entrada Therapeutics (TRDA) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Entrada Therapeutics (NASDAQ:TRDA) Stock
Entrada Therapeutics Stock (NASDAQ: TRDA)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, November 06, 2024
Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock
Benzinga Insights
Oppenheimer Maintains Outperform on Entrada T...
Benzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Entrada ...
Benzinga Newsdesk
Tuesday, November 05, 2024
Entrada Therapeutics Says Cash Runway Expecte...
Benzinga Newsdesk
Entrada Therapeutics Q3 2024 GAAP EPS $(0.35)...
Benzinga Newsdesk
Wednesday, October 09, 2024
Entrada Therapeutics Announced The Presentati...
Benzinga Newsdesk
Monday, August 26, 2024
Oppenheimer Reiterates Outperform on Entrada ...
Benzinga Newsdesk
Thursday, August 15, 2024
AstraZeneca Imfinzi Combo Gets EU Nod for Uterine Cancer
Zacks
Wednesday, August 14, 2024
Evotec Rises 12% on $75M Milestone Payment From BMY
Zacks
HC Wainwright & Co. Reiterates Buy on Entrada...
Benzinga Newsdesk
Tuesday, August 13, 2024
Entrada Therapeutics shares are trading highe...
Benzinga Newsdesk
Entrada Therapeutics' Cash Runway Expected In...
Benzinga Newsdesk
Entrada Therapeutics Q2 2024 GAAP EPS $1.55 M...
Benzinga Newsdesk
Friday, August 09, 2024
Nektar's Q2 Earnings Lag Estimates, Revenues Top
Zacks
Thursday, August 08, 2024
SpringWorks Q2 Earnings Beat, Ogsiveo Drives Revenues
Zacks
Wednesday, July 31, 2024
United Therapeutics Q2 Earnings Lag, Sales Top Estimates
Zacks
Thursday, July 18, 2024
Alterity Up on Interim Data From Advance MSA Study
Zacks
Thursday, July 11, 2024
Zevra Rises on Update on Niemann-Pick Disease Type C Drug
Zacks
Tuesday, June 25, 2024
HC Wainwright & Co. Maintains Buy on Entrada ...
Benzinga Newsdesk
Monday, June 24, 2024
Entrada Therapeutics To Raise $100M Via Regis...
Benzinga Newsdesk
Entrada Therapeutics Announced Preliminary Da...
Benzinga Newsdesk
Tuesday, May 07, 2024
Entrada Therapeutics Expects Cash Runway Thro...
Benzinga Newsdesk
Entrada Therapeutics Q1 2024 GAAP EPS $0.68 M...
Benzinga Newsdesk
Thursday, April 11, 2024
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
Insiders Buying America's Car-Mart And 2 Other Stocks
Avi Kapoor
Friday, March 22, 2024
Around $5M Bet On This Communication Services Stock? Check Out These 4 Stocks Insiders Are Buying
Avi Kapoor
Monday, March 18, 2024
HC Wainwright & Co. Reiterates Buy on Entrada...
Benzinga Newsdesk
Wednesday, March 13, 2024
Recap: Entrada Therapeutics Q4 Earnings
Benzinga Insights
Entrada Therapeutics' Cash Balance Of $352M W...
Benzinga Newsdesk
Entrada Therapeutics Q4 GAAP EPS $(0.29) Miss...
Benzinga Newsdesk
Friday, January 05, 2024
Entrada Therapeutics shares are trading highe...
Benzinga Newsdesk
Oppenheimer Initiates Coverage On Entrada The...
Benzinga Newsdesk
Monday, November 27, 2023
HC Wainwright & Co. Maintains Buy Rating for Entrada Therapeutics: Here's What You Need To Know
Benzinga Insights
HC Wainwright & Co. Maintains Buy on Entrada ...
Benzinga Newsdesk
Thursday, November 23, 2023
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
Wednesday, November 22, 2023
Why Is Neuromuscular Disease Focused Entrada Therapeutics Shares Trading Lower Today?
Vandana Singh
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
Entrada Therapeutics shares are trading lower...
Benzinga Newsdesk
Entrada Says FDA Clinical Hold On ENTR-601-44...
Benzinga Newsdesk
Entrada Plans To Announce Data From ENTR-601-...
Benzinga Newsdesk
Tuesday, November 07, 2023
Entrada Therapeutics' Cash Runway Expected Th...
Benzinga Newsdesk
Entrada Therapeutics Q3 EPS $1.02 May Not Be ...
Benzinga Newsdesk
Friday, September 22, 2023
HC Wainwright & Co. Reiterates Buy on Entrada...
Benzinga Newsdesk
Thursday, September 21, 2023
Entrada Therapeutics Announces First Particip...
Benzinga Newsdesk
Wednesday, August 09, 2023
HC Wainwright & Co. Reiterates Buy on Entrada...
Benzinga Newsdesk
Tuesday, August 08, 2023
Entrada Therapeutics shares are trading highe...
Benzinga Newsdesk
Entrada Therapeutics Q2 EPS $(0.78) Down From...
Benzinga Newsdesk
Wednesday, August 02, 2023
HC Wainwright & Co. Reiterates Buy on Entrada...
Benzinga Newsdesk
Monday, June 26, 2023
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
Wednesday, May 24, 2023
HC Wainwright & Co. Reiterates Buy on Entrada...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
